Mylan hosted its Q4 and full-year 2016 earnings call in conjunction with its investor day and provided an update to the insulin pipeline.
Merck/Pfizer quietly filed their SGLT2i, ertugliflozin, FDC with metformin, and FDC with Januvia (sitagliptin) in December 2016.
Lexicon recently presented at the Leerink Global Healthcare Conference and provided updates to its diabetes development programs.
EMA has issued a warning that Invokana is associated with increased cases of lower limb amputations, particularly toes, in the CANVAS and CANVAS-R studies. The underlying cause remains unknown. While EMA has concluded the risk exists, the issue remains under investigation with FDA.
Merck hosted their Q4 and full-year 2016 earnings update today. Overall, there was minimal diabetes-related discussion as the primary focus was on Keytruda.